Longeveron Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
LGVN Nasdaq 8731 https://www.longeveron.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Longeveron Inc

Longeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public Offering - Apr 18th, 2024 8:05 pm
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds - Apr 17th, 2024 12:00 pm
LGVN Takes Steps Toward Success - Apr 16th, 2024 12:59 pm
Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC) - Apr 15th, 2024 12:30 pm
Chief Scientific Officer Joshua Hare Acquires 148,936 Shares of Longeveron Inc (LGVN) - Apr 13th, 2024 5:39 am
Longeveron Announces Closing of $5.2 Million Public Offering - Apr 11th, 2024 9:17 pm
Longeveron Announces Pricing of $5.25 Million Public Offering - Apr 8th, 2024 6:15 pm
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals - Apr 8th, 2024 12:30 pm
Longeveron Announces 1-for-10 Reverse Stock Split - Mar 19th, 2024 8:01 pm
Longeveron Full Year 2023 Earnings: EPS Misses Expectations - Mar 1st, 2024 10:17 am
Longeveron Inc. (NASDAQ:LGVN) Q4 2023 Earnings Call Transcript - Feb 28th, 2024 2:19 pm
LGVN Sharpens Focus on Heart Treatment - Feb 28th, 2024 11:49 am
Longeveron Reports Year-End 2023 Results and Provides Corporate Update - Feb 27th, 2024 9:05 pm
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024 - Feb 21st, 2024 9:05 pm
Longeveron Receives Notice of United States Patent Allowance for the Technology Behind its Lead Investigation Product Lomecel-B™ - Jan 29th, 2024 1:00 pm
Longeveron Announces Closing of $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Dec 22nd, 2023 9:05 pm
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Dec 21st, 2023 3:34 pm
Longeveron Announces $2.36 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - Dec 21st, 2023 1:00 pm
Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease - Dec 20th, 2023 1:00 pm
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc. - Nov 14th, 2023 1:17 pm